The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of everolimus (E) in refractory germ cell tumors (GCTs).
Michal Mego
No relevant relationships to disclose
Daniela Svetlovska
No relevant relationships to disclose
Jana Obertova
No relevant relationships to disclose
Maria Reckova
No relevant relationships to disclose
Viera Miskovska
No relevant relationships to disclose
Jan Rajec
No relevant relationships to disclose
Zuzana Sycova-Mila
No relevant relationships to disclose
Patrik Palacka
No relevant relationships to disclose
Stefania Liskova
No relevant relationships to disclose
Michal Chovanec
No relevant relationships to disclose
Tomas Salek
No relevant relationships to disclose
Jozef Mardiak
No relevant relationships to disclose